Novartis said that its immunology drug Cosentyx met the primary target and all secondary ones in a late-stage trial for the treatment of patients with inflammatory disease polymyalgia rheumatica.

Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in annual cumulative steroid dose vs placebo ...

Novartis Cosentyx meets primary and all secondary endpoints in phase III trial in patients with polymyalgia rheumatica: Basel Thursday, October 23, 2025, 09:00 Hrs [IST] Novartis ...

Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing ...

In a study from Korea, adults with type 2 diabetes had a lower risk for autoimmune rheumatic diseases after starting an SGLT2 ...

The Global Healthy Living Foundation (GHLF), parent non-profit of the CreakyJoints® online patient community, today announced ...

Novartis (NVS) today announced that Cosentyx met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial. Cosentyx ...

Learn how vitamin D functions and may affect diabetes, heart disease, cancer, and dementia risk. Plus, how it could benefit ...

Levofloxacin-induced myopathy is a relatively under-recognized adverse effect. Here, we present a case of myopathy affecting the iliac and gluteal muscles caused by the administration of levofloxacin.

I read your recent column where you said that ivermectin has not been proven to be an effective treatment for cancer. I feel ...

Autoimmune neuromuscular diseases may sound complex, but understanding them is the first step to getting the right care and ...